Galen: Galen acquires US rights to Adasuve inhaled loxapine

Galen US has acquired US rights to Alexza Pharmaceuticals' Adasuve inhaled loxapine for the treatment of agitation in patients with schizophrenia or bipolar I. Adasuve was approved by the FDA in December 2012 for use in certain healthcare facilities enrolled in the Adasuve REMS program only. In May 2013, Teva announced that it had acquired [...]